This week, at the American College of Cardiology meetings, investigators made their formal scientific presentation of data from their studies with rimonabant, the first of a new class of drugs aimed at helping with weight loss, metabolic disorders, and smoking cessation. DrRich was there, and here is his analysis.
Comments
No comments yet. Leave a Comment

